Proficio Capital Partners LLC raised its position in Allergan PLC (NYSE:AGN) by 624.5% during the second quarter, according to its most recent disclosure with the SEC. The firm owned 4,115 shares of the company’s stock after buying an additional 3,547 shares during the period. Proficio Capital Partners LLC’s holdings in Allergan PLC were worth $1,052,000 at the end of the most recent quarter.
A number of other institutional investors have also added to or reduced their stakes in the company. Barnett & Company Inc. acquired a new position in Allergan PLC during the first quarter worth $111,000. Livingston Group Asset Management CO operating as Southport Capital Management purchased a new stake in Allergan PLC during the second quarter valued at approximately $125,000. Trust Co. of Vermont raised its stake in Allergan PLC by 19.5% in the second quarter. Trust Co. of Vermont now owns 545 shares of the company’s stock valued at $126,000 after buying an additional 89 shares during the period. Integrated Investment Consultants LLC raised its stake in Allergan PLC by 35.2% in the second quarter. Integrated Investment Consultants LLC now owns 592 shares of the company’s stock valued at $137,000 after buying an additional 154 shares during the period. Finally, High Point Bank & Trust Co. raised its stake in Allergan PLC by 19.9% in the second quarter. High Point Bank & Trust Co. now owns 692 shares of the company’s stock valued at $160,000 after buying an additional 115 shares during the period. 85.20% of the stock is owned by institutional investors.
Allergan PLC (NYSE:AGN) traded down 1.56% during trading on Monday, reaching $223.99. The company had a trading volume of 3,669,952 shares. The company has a market capitalization of $88.69 billion, a PE ratio of 21.33 and a beta of 0.81. Allergan PLC has a 52-week low of $195.50 and a 52-week high of $322.68. The stock has a 50 day moving average price of $238.01 and a 200-day moving average price of $238.04.
Allergan PLC (NYSE:AGN) last released its earnings results on Monday, August 8th. The company reported $3.35 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $3.34 by $0.01. The firm earned $3.68 billion during the quarter, compared to analysts’ expectations of $4.10 billion. Allergan PLC had a net margin of 28.06% and a return on equity of 7.67%. Allergan PLC’s revenue for the quarter was up 1.0% on a year-over-year basis. During the same period in the previous year, the company earned $4.41 EPS. On average, equities research analysts anticipate that Allergan PLC will post $14.00 earnings per share for the current fiscal year.
Several equities research analysts have commented on the company. Deutsche Bank AG set a $278.00 price objective on Allergan PLC and gave the stock a “buy” rating in a research note on Saturday. Vetr lowered Allergan PLC from a “strong-buy” rating to a “buy” rating and set a $283.05 price objective for the company. in a research note on Monday, August 8th. RBC Capital Markets reiterated an “outperform” rating and set a $300.00 price objective (down from $307.00) on shares of Allergan PLC in a research note on Wednesday, August 10th. Leerink Swann set a $294.00 price objective on Allergan PLC and gave the stock a “buy” rating in a research note on Monday, August 8th. Finally, JPMorgan Chase & Co. set a $325.00 price objective on Allergan PLC and gave the stock a “buy” rating in a research note on Friday, August 5th. Six investment analysts have rated the stock with a hold rating, eighteen have given a buy rating and one has given a strong buy rating to the company. The stock currently has a consensus rating of “Buy” and an average price target of $302.23.
About Allergan PLC
Allergan, Inc is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets.
Want to see what other hedge funds are holding AGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Allergan PLC (NYSE:AGN).
Receive News & Ratings for Allergan PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan PLC and related companies with MarketBeat.com's FREE daily email newsletter.